Amedisys (AMED) Competitors

Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk.

Does the MarketBeat Community favor AMED or DVA?

DaVita received 1 more outperform votes than Amedisys when rated by MarketBeat users. Likewise, 61.16% of users gave DaVita an outperform vote while only 58.58% of users gave Amedisys an outperform vote.

Company	Underperform	Outperform
Amedisys	Outperform Votes 495 58.58%	Underperform Votes 350 41.42%
DaVita	Outperform Votes 496 61.16%	Underperform Votes 315 38.84%

Which has more volatility and risk, AMED or DVA?

Amedisys has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, DaVita has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.

Which has preferable earnings and valuation, AMED or DVA?

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amedisys	$2.35B	1.30	-$9.75M	$1.31	70.77
DaVita	$12.82B	0.95	$936.34M	$10.74	14.18

Is AMED or DVA more profitable?

DaVita has a net margin of 7.31% compared to Amedisys' net margin of 3.57%. DaVita's return on equity of 115.48% beat Amedisys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amedisys	3.57%	12.20%	6.74%
DaVita	7.31%	115.48%	4.94%

Do analysts prefer AMED or DVA?

Amedisys presently has a consensus price target of $101.00, suggesting a potential upside of 8.94%. DaVita has a consensus price target of $166.33, suggesting a potential upside of 9.19%. Given DaVita's higher probable upside, analysts clearly believe DaVita is more favorable than Amedisys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amedisys	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DaVita	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media favor AMED or DVA?

In the previous week, DaVita had 12 more articles in the media than Amedisys. MarketBeat recorded 15 mentions for DaVita and 3 mentions for Amedisys. Amedisys' average media sentiment score of 1.30 beat DaVita's score of 1.04 indicating that Amedisys is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amedisys	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	13 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders hold more shares of AMED or DVA?

94.4% of Amedisys shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 2.1% of Amedisys shares are owned by company insiders. Comparatively, 2.0% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

DaVita beats Amedisys on 11 of the 17 factors compared between the two stocks.